Pfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S. investments in research and manufacturing, according to CNBC. In the company's first-quarter earnings call, Bourla said that a clear, stable trade policy would unlock tremendous domestic spending in research and manufacturing. Pfizer’s full-year guidance remains unchanged but does not account for future tariff impacts. CFO Dave Denton said current guidance includes $150 million in costs from existing tariffs and that the company still expects to reach the upper end of its forecast range.
